Mark. A Glickman
2018
Compensation breakdown
| Non-Equity Incentive Plan | $190,000 |
|---|---|
| Option Awards | $7,147,108 |
| Salary | $322,500 |
| Stock Awards | $1,345,800 |
| Other | $9,250 |
| Total | $9,014,658 |
Glickman received $7.1M in option awards, accounting for 79% of the total pay in 2018.
Glickman also received $190K in non-equity incentive plan, $322.5K in salary, $1.3M in stock awards and $9.3K in other compensation.
Rankings
In 2018, Mark. A Glickman's compensation ranked 832nd out of 14,244 executives tracked by ExecPay. In other words, Glickman earned more than 94.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 832 out of 14,244 | 94th |
Division Manufacturing | 278 out of 5,759 | 95th |
Major group Chemicals And Allied Products | 81 out of 2,122 | 96th |
Industry group Drugs | 64 out of 1,811 | 97th |
Industry Pharmaceutical Preparations | 43 out of 1,385 | 97th |
Pay ratio
| Mark. A Glickman's Pay | $9,014,658 |
|---|---|
| Median Employee's Pay | $601,814 |
| Pay Ratio | 15to 1 |
In 2018, the annual total compensation of Mark. A Glickman was $9,014,658.
The annual total compensation of the median employee at Esperion Therapeutics was $601,814.
The ratio of Mark. A Glickman's pay to the pay of median employee was therefore 15 to one.
Glickman's colleagues
We found three more compensation records of executives who worked with Mark. A Glickman at Esperion Therapeutics in 2018.